| John Boyajian, MD | |
|
3085 E Magic View Dr # 140, Meridian, ID 83642-3757 | |
| (208) 433-9300 | |
| (208) 433-9854 |
| Full Name | John Boyajian |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 52 Years |
| Location | 3085 E Magic View Dr # 140, Meridian, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942205604 | NPI | - | NPPES |
| 003581300 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0602X | Otolaryngology - Otolaryngic Allergy | M6896 (Idaho) | Secondary |
| 207Y00000X | Otolaryngology | M6896 (Idaho) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Specialty Clinics Of Idaho Inc | 3072619683 | 2 |
News Archive
The University of California, Riverside announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Eamonn Keogh, a professor of computer science in the Bourns College of Engineering, will pursue an innovative global health and development research project, titled, "Inciting Healthy Behaviors: Nudging using Prompt-Execute-Gauge, a Human Computation Game."
Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.
Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.
IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented "This is a significant step forward in validating IGI's commitment to pharmaceutical product development.
Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.
› Verified 6 days ago
| Entity Name | Specialty Clinics Of Idaho Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174671481 PECOS PAC ID: 3072619683 Enrollment ID: O20070427000314 |
News Archive
The University of California, Riverside announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Eamonn Keogh, a professor of computer science in the Bourns College of Engineering, will pursue an innovative global health and development research project, titled, "Inciting Healthy Behaviors: Nudging using Prompt-Execute-Gauge, a Human Computation Game."
Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.
Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.
IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented "This is a significant step forward in validating IGI's commitment to pharmaceutical product development.
Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Boyajian, MD 3085 E Magic View Dr # 140, Meridian, ID 83642-3757 Ph: (208) 433-9300 | John Boyajian, MD 3085 E Magic View Dr # 140, Meridian, ID 83642-3757 Ph: (208) 433-9300 |
News Archive
The University of California, Riverside announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Eamonn Keogh, a professor of computer science in the Bourns College of Engineering, will pursue an innovative global health and development research project, titled, "Inciting Healthy Behaviors: Nudging using Prompt-Execute-Gauge, a Human Computation Game."
Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.
Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.
IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented "This is a significant step forward in validating IGI's commitment to pharmaceutical product development.
Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.
› Verified 6 days ago
Dr. Eric Peter Wilkinson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1209 N Summerbrook Ave Ste 100, Meridian, ID 83642 Phone: 208-938-5823 Fax: 208-938-5306 | |
Dr. James Vincent Crawford, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1209 N Summerbrook Ave Ste 100, Meridian, ID 83642 Phone: 208-938-5823 Fax: 208-938-5306 | |
Lance Wayne Coleman, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 520 S Eagle Rd, #1223, Meridian, ID 83642 Phone: 208-888-4368 | |
Dr. Jacob Scott Majors, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 875 S Vanguard Way Ste 200, Meridian, ID 83642 Phone: 208-809-2895 Fax: 208-809-2896 | |
Dr. Peter James Killian, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1157 N Summerbrook Ave Ste 120, Meridian, ID 83642 Phone: 208-593-4484 Fax: 208-593-4491 |